Tomas
Sobrino Moreiras
Universidad de Sevilla
Sevilla, EspañaPublicacións en colaboración con investigadores/as de Universidad de Sevilla (5)
2024
-
Correction to: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial (Nature Communications, (2024), 15, 1, (5251), 10.1038/s41467-024-49121-3)
Nature Communications
-
Correction to: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe (Nature Communications, (2024), 15, 1, (3736), 10.1038/s41467-024-47751-1)
Nature Communications
-
dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe
Nature Communications, Vol. 15, Núm. 1
2022
-
Multi-Ancestry GWAS reveals excitotoxicity associated with outcome after ischaemic stroke
Brain, Vol. 145, Núm. 7, pp. 2394-2406
2019
-
Genome-wide association study of white blood cell counts in patients with ischemic stroke
Stroke, Vol. 50, Núm. 12, pp. 3618-3621